Novo Nordisk Raises Guidance as Wegovy Sales Exceed Expectations
Novo Nordisk reported first-quarter sales of $15.2 billion, surpassing analyst forecasts, driven by strong performance of its weight-loss drugs, including the newly launched Wegovy pill. The company raised its 2026 full-year guidance despite projecting a contraction in adjusted sales and operating profit.
Tickers: $NVO
Topics: earnings GLP-1 drugs Ozempic pharmaceuticals sales guidance Wegovy